Janossy G, Roberts M, Greaves M F, Woodruff R, Pippard M, Prentice G, Hoffbrand A V
Boll Ist Sieroter Milan. 1978 Jul 31;57(3):355-9.
Membrane markers (anti-ALL and anti-Ia antisera) and an enzyme marker (terminal transferase) have been used to define an L-type or "lymphoid" type of acute transformation in chronic myeloid leukaemia and Ph1 positive acute leukaemia. Patients with L-type ("lymphoid") blasts responded to regimens including vincristine and prednisolone (VP). The markers showed better correlation with survival than did the morphology of blasts. The clinical course of patients was variable; elimination Ph1 positive clone (and hypoplasia), return to the chronic phase and relapses (including meningeal leukaemia) were observed. In contrast, patients with myeloid blasts ("M" type of blast crisis) failed to respond to vincristine and prednisolone.
膜标记物(抗 ALL 和抗 Ia 抗血清)以及一种酶标记物(末端转移酶)已被用于定义慢性粒细胞白血病和 Ph1 阳性急性白血病中的 L 型或“淋巴样”急性转化类型。L 型(“淋巴样”)原始细胞的患者对包括长春新碱和泼尼松龙(VP)在内的治疗方案有反应。这些标记物与生存期的相关性比原始细胞的形态学更好。患者的临床病程各不相同;观察到 Ph1 阳性克隆的消除(以及发育不全)、回到慢性期和复发(包括脑膜白血病)。相比之下,具有髓样原始细胞的患者(“M”型原始细胞危象)对长春新碱和泼尼松龙无反应。